Ultragenyx agrees to sell voucher for US$210M
Ultragenyx Pharmaceutical (NASDAQ: RARE) agreed to sell a rare pediatric disease priority review voucher for $210M, nearly half its cash reserves. The deal, subject to regulatory approval, follows the FDA's August approval of its Genglycos gene therapy. Shares rose 2.97% on the news. Ultragenyx plans to use proceeds to advance rare disease therapies and support profitability. The price is within the range of recent voucher transactions, such as Rocket Pharmaceuticals' $180M deal.
How this was made
The 30-second read
Why it matters
The deal adds significant non‑dilutive capital, improves cash position, and has already moved the stock higher.
Market read
Primary disclosure of a large voucher sale that impacts Ultragenyx's valuation and may set a precedent for biotech financing.
What to watch
Buyer identity and closing conditions remain unknown, and regulatory review could affect timing.
Background
Ultragenyx Pharmaceutical announced a $210M agreement to sell a priority review voucher earned from an FDA approval, with shares up 2.97% at the close.
Ticker impact
Ultragenyx agreed to sell a rare‑pediatric disease priority review voucher for $210M, prompting a 2.97% share rise.
likely modest upside as the market prices in the $210M cash infusion
Voucher monetization adds cash, reduces dilution concerns, and triggered a near‑3% price jump.
Market effects
Biotech firms may view voucher sales as a new financing tool, potentially boosting sector valuations.
US biotech investors could see increased interest in rare‑disease pipelines.
Other rare‑disease companies worldwide may consider similar voucher monetizations.
Counterpoint
The need to sell a voucher may signal cash constraints, raising concerns about Ultragenyx's runway.
Key entities
- companyUltragenyx Pharmaceutical Inc.
US biotech developing rare disease therapies; ticker RARE.
- companyRocket Pharmaceuticals, Inc.
Referenced peer that sold a voucher for $180M.
- companyFortress Biotech, Inc.
Referenced peer with a $205M voucher sale.
